LONDON, Nov. 28, 2017 /PRNewswire/ -- SummaryInterleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.Download the full report: https://www.reportbuyer.com/product/5214362Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Metabolic Disorders, Oncology, Cardiovascular, Dermatology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ear Nose Throat Disorders and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Epidermolysis Bullosa, Inflammation, Non-Small Cell Lung Cancer, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Rheumatoid Arthritis, Type 2 Diabetes, Acne Vulgaris, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cachexia, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).The latest report Interleukin 1 (IL1) - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type- The report summarizes all the dormant and discontinued pipeline projects- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeuticsReasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)- Identify the use of drugs for target identification and drug repurposing- Identify potential new clients or partners in the target demographic- Develop strategic initiatives by understanding the focus areas of leading companies- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeDownload the full report: https://www.reportbuyer.com/product/5214362
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/interleukin-1-il1---pipeline-review-h2-2017-300562810.html
SOURCE ReportBuyer
